Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury

Pharmacology

Volumn 85, Issue 3, 2010, Pages 158-167

  Fouad, Amr A ^a   Qureshi, Habib A ^a   Al Sultan, Ali Ibrahim ^a   Yacoubi, Mohamed T ^a   Al Melhim, Walid N ^a  

^a KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Inflammation; Ischemia; Kidney; Oxidative stress; Reperfusion; Telmisartan

Indexed keywords

CASPASE 3; CATALASE; CREATININE; GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; KIDNEY ISCHEMIA; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; REPERFUSION INJURY; UREA NITROGEN BLOOD LEVEL; VASCULAR PEDICLE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD UREA NITROGEN; CASPASE 3; CATALASE; CREATININE; DISEASE MODELS, ANIMAL; GLUTATHIONE; HOMOCYSTEINE; KIDNEY; KIDNEY DISEASES; MALE; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76249120050     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000269779     Document Type: Article

References (47)

1. Ploeg RJ, van Bockel JH, Langendijk PT, Groenewegen M, van der Woude FJ, Persijn GG, Thorogood J, Hermans J: Effect of preservation solution on results of cadaveric kidney transplantation. The European Multicentre Study Group. Lancet 1992;340:129-137.
2. Edelstein CL, Ling H, Schrier RW: The nature of renal cell injury. Kidney Int 1997;51:1341-1351.
3. Rah DK, Han DW, Baek HS, Hyon SH, Park BY, Park JC: Protection of rabbit kidney from ischemia/reperfusion injury by green tea polyphenol pre-treatment. Arch Pharm Res 2007;30:1447-1454.
4. Cau J, Favreau F, Zhang K, Febrer G, de la Motte GR, Ricco JB, Goujon JM, Hauet T: FR167653 improves renal recovery and decreases inflammation and fibrosis after renal ischemia reperfusion injury. J Vasc Surg 2009;49:728-740.
5. Korkmaz A, Kolankaya D: The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats. Ren Fail 2009;31:36-43.
6. Seujange Y, Eiam-Ong S, Tirawatnapong T, Eiam-Ong S: Role of angiotensin II on dihydrofolate reductase, GTP-cyclohydrolase 1 and nitric oxide synthase expressions in renal ischemia-reperfusion. Am J Nephrol 2008;28:692-700.
7. Park JK, Mervaala EM, Muller DN, Menne J, Fiebeler A, Luft FC, Haller H: Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertens 2009;27:599-605.
8. Prathapasinghe GA, Siow YL, Karmin O: Detrimental role of homocysteine in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2007;292:F1354-F1363.
9. Barnett AH: Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalapril (DETAIL) study. Acta Diabetol 2005;42:S42-S49.
10. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S: The telmisartan renoprotective study from incipient nephropathy to overt nephropathy - rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. J Int Med Res 2005;33:677-686.
11. Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, de Novales E: Longterm renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005;46:1074-1079.
12. Wienen W, Richard S, Champeroux P, Audeval-Gerard C: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2001;2:31-36.
13. Mandarim-de-Lacerda CA, Pereira LM: Effects of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histol Histopathol 2004;19: 727-733.
14. Tsunenari I, Ohmura T, Seidler R, Chachin M, Hayashi T, Konomi A, Matsumaru T, Sumida T, Hayashi N, Yoshiharu Horie Y: Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. J Renin Angiotensin Aldosterone Syst 2007;8:93-100.
15. Cibulskyte D, Pedersen M, Hørlyck A, Marcussen N, Hansen HE, Frøkiær J, Madsen M, Mortensen J: Telmisartan attenuates chronic ciclosporin A nephrotoxicity in a pig model. Nephrol Dial Transplant 2007;22:369-375.
16. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004;43:993-1002.
17. Cianchetti S, Del Fiorentino A, Colognato R Di Stefano R, Franzoni F, Pedrinelli R: Antiinflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008;198:22-28.
18. Molinas SM, Cortés-González C, GonzálezBobadilla Y, Monasterolo LA, Cruz C, Elías MM, Bobadilla NA, Trumper L: Effects of losartan pretreatment in an experimental model of ischemic acute kidney injury. Nephron Exp Nephrol 2009;112:e10-e19.
19. Kakuta H, Sudoh K, Sasamatsu M, Yamagishi S: Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor blockers. Int J Clin Pharm Res 2005;25:41-46.
20. Iwai M, Inaba S, Tomono Y, Kanno H, Iwanami J, Mogi M, Horiuchi M: Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 2008;31:161-168.
21. Wang Y, Pei DS, Ji HX, Xing SH: Protective effect of a standardized Ginkgo extract (ginaton) on renal ischemia/reperfusion injury via suppressing the activation of JNK signal pathway. Phytomedicine 2008;15:923-931.
22. Volti GL, Sorrenti V, Murabito P, Galvano F, Veroux M, Gullo A, Acquaviva R, Stacchiotti A, Bonomini F, Vanella L, Di Giacomo C: Pharmacological induction of heme oxygenase-1 inhibits iNOS and oxidative stress in renal ischemia-reperfusion injury. Transplant Proc 2007;39:2986-2991.
23. Cai H, Griendling KK, Harrison DG: The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003;24:471-478.
24. Neto JS, Nakao A, Kimizuka K, Romanosky AJ, Stolz DB, Uchiyama T, Nalesnik MA, Otterbein LE, Murase N: Protection of trans-plant-induced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol 2004;287:F979-F989.
25. Jia RP, Zhu JG, Wu JP, Xie JJ, Xu LW: Experimental study on early protective effect of ischemic preconditioning on rat kidney graft. Transplant Proc 2009;41:69-72.
26. Salom MG, Cerón SN, Rodriguez F, Lopez B, Hernández I, Martínez JG, Losa AM, Fenoy FJ: Heme oxygenase-1 induction improves ischemic renal failure: role of nitric oxide and peroxynitrite. Am J Physiol Heart Circ Physiol 2007;293:H3542-H3549.
27. Guven A, Uysal B, Akgul O, Cermik H, Gundogdu G, Surer I, Ozturk H, Korkmaz A: Scavenging of peroxynitrite reduces renal ischemia/reperfusion injury. Ren Fail 2008;30:747-754.
28. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R: Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006;29:849-856.
29. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T: Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol 2006;41:989-997.
30. Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, Fujita T: Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 2007;25:1643-1649.
31. Kagota S, Tada Y, Nejime N, Nakamura K, Kunitomo M, Shinozuka K: Chronic production of peroxynitrite in the vascular wall impairs vasorelaxation function in SHR/NDmcr-cp rats, an animal model of metabolic syndrome. J Pharmacol Sci 2009;109:556-564.
32. Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, Yamasaki Y, Masuoka N, Kira S, Makino H: Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 2005;20:2670-2680.
33. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, Inoue N, Hirata K, Yokoyama M: Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein Edeficient mice. Atherosclerosis 2006;186:402-410.
34. Kaschina E, Schrader F, Sommerfeld M, Kemnitz UR, Grzesiak A, Krikov M, Unger T: Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens 2008;26:2361-2373.
35. 2+ channel expression in neonatal rat cardiomyocytes. Eur J Pharmacol 2009;609:105-112.
36. Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK: Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007;322:1051-1058.
37. Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H: Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2008;21:576-581.
38. Nakamura T, Keep RF, Hua Y, Hoff JT, Xi G: Oxidative DNA injury after experimental intracerebral hemorrhage. Brain Res 2005;1039:30-36.
39. Blessing E, Preusch M, Kranzhöfer R, Kinscherf R, Marx N, Rosenfeld ME, Isermann B, Weber CM, Kreuzer J, Gräfe J, Katus HA, Bea F: Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis 2008;199:295-303.
40. Dimitropoulou C, Chatterjee A, McClud L, Tetik-Anacak G, Catravas JD: Angiotensin, bradykinin and the endothelium; in Moncada S, Higgs A (eds): The Vascular Endothelium I. Berlin, Springer, 2006, pp 255-290.
41. Mehta PK, Griendling KK: Angiotensin II cell signalling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97.
42. Diez N, Perez R, Hurtado V, Santidrian S: Hyperhomocysteinaemia induced by dietary folate restriction causes kidney oxidative stress in rats. Br J Nutr 2005;94:204-210.
43. Prathapasinghe GA, Siow YL, Xu Z, Karmin O: Inhibition of cystathionine-β-synthase activity during renal ischemia-reperfusion: role of pH and nitric oxide. Am J Physiol Renal Physiol 2008;295:F912-F922.
44. Baden T, Yamawaki H, Saito K, Mukohda M, Okada M, Hara Y: Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium. Biochem Biophys Res Commun 2008;373:253-257.
45. Faubion WA, Gores GJ: Death receptors in liver biology and pathobiology. Hepatology 1999;29:1-4.
46. Basnakian AG, Kaushal GP, Shah SV: Apoptotic pathways of oxidative damage to renal tubular epithelial cells. Antioxid Redox Signal 2002;4:915-924.
47. Williams P, Lopez H, Britt D, Chan C, Ezrin A, Hottendorf R: Characterization of renal ischemia-reperfusion injury in rats. Pharmacol Toxicol Methods 1997;37:1-7.